Kellokumpu-Lehtinen, P., J. Bergh, E. Salminen, T. Wiklund, S. Lehtinen, P. Aronen, and H. Sintonen. 2007. “Cost-Effectiveness of Intensive Adjuvant Chemotherapy for High-Risk Breast Cancer: Is Tailored and Dose-Escalated Chemotherapy With Growth Factor Support (GFS) More Costly and Less Effective Than Marrow-Supported High-Dose Chemotherapy – Results from a Ra”. Acta Oncologica 46 (2):146-52. https://doi.org/10.1080/02841860600965012.